One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Both the mirror and manufacturer print 1.72 m2 for renal PK; the manufacturer also uses 1.73 m2 for trial exclusion. This is not an isolated mirror transcription error.
What to reconcile: Do not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
Open this note and its source referencesDo not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
| Source renal population | Source-specific instruction |
|---|---|
| eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2) | No clinically significant pharmacokinetic difference reported. |
| Pre-existing severe renal impairment | Not studied; weigh risks and benefits before starting. |
REZUROCK - renal evidence, not a dose ladder
| Source renal population | Source-specific instruction |
|---|---|
| eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2) | No clinically significant pharmacokinetic difference reported. |
| Pre-existing severe renal impairment | Not studied; weigh risks and benefits before starting. |
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
RDM64-official-belumosudil-rezurock-a7ba1181bc-C1 · Source locator: Sections 2.1-2.3, 8.6, 12.3, 14.1; manufacturer PDF pages 1, 3 and 4 inspected.
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=belumosudil-rezurock&s1=RDM64-official-belumosudil-rezurock-a7ba1181bc&h1=afb7712d054688ce15cf40691edec5b617fcabed46bd7dde1120ade0cfbbf395